Literature DB >> 20358258

QM/MM based 3D QSAR models for potent B-Raf inhibitors.

Jae Yoon Chung1, Hwan Won Chung, Seung Joo Cho, Jung-Mi Hah, Art E Cho.   

Abstract

Three dimensional (3D) quantitative structure-activity relationship studies of 37 B-Raf inhibitors, pyrazole-based derivatives, were performed. Based on the co-crystallized compound (PDB ID: 3D4Q), several alignment methods were utilized to derive reliable comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) models. Receptor-guided alignment with quantum mechanics/molecular mechanics (QM/MM) minimization led to the best CoMFA model (q (2) = 0.624, r (2) = 0.959). With the same alignment, a statistically reliable CoMSIA model with steric, H-bond acceptor, and hydrophobic fields was also derived (q (2) = 0.590, r (2) = 0.922). Both models were validated with an external test set, which gave satisfactory predictive r (2) values of 0.926 and 0.878, respectively. Contour maps from CoMFA and CoMSIA models revealed important structural features responsible for increasing biological activity within the active site and explained the correlation between biological activity and receptor-ligand interactions. New fragments were identified as building blocks which can replace R1-3 groups through combinatorial screening methods. By combining these fragments a compound with a high bioactivity level prediction was found. These results can offer useful information for the design of new B-Raf inhibitors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20358258     DOI: 10.1007/s10822-010-9337-5

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  16 in total

1.  Prediction of n-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices.

Authors:  I V Tetko; V Y Tanchuk; A E Villa
Journal:  J Chem Inf Comput Sci       Date:  2001 Sep-Oct

Review 2.  Protein kinase inhibitors: insights into drug design from structure.

Authors:  Martin E M Noble; Jane A Endicott; Louise N Johnson
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

3.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

Authors:  R D Cramer; D E Patterson; J D Bunce
Journal:  J Am Chem Soc       Date:  1988-08-01       Impact factor: 15.419

Review 4.  The RAF proteins take centre stage.

Authors:  Claudia Wellbrock; Maria Karasarides; Richard Marais
Journal:  Nat Rev Mol Cell Biol       Date:  2004-11       Impact factor: 94.444

5.  Potent and selective pyrazole-based inhibitors of B-Raf kinase.

Authors:  Joshua D Hansen; Jonas Grina; Brad Newhouse; Mike Welch; George Topalov; Nicole Littman; Michele Callejo; Susan Gloor; Matthew Martinson; Ellen Laird; Barbara J Brandhuber; Guy Vigers; Tony Morales; Rich Woessner; Nikole Randolph; Joseph Lyssikatos; Alan Olivero
Journal:  Bioorg Med Chem Lett       Date:  2008-07-05       Impact factor: 2.823

6.  CoMFA and docking studies of 2-phenylindole derivatives with anticancer activity.

Authors:  Si Yan Liao; Li Qian; Ti Fang Miao; Hai Liang Lu; Kang Cheng Zheng
Journal:  Eur J Med Chem       Date:  2008-12-25       Impact factor: 6.514

7.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity.

Authors:  G Klebe; U Abraham; T Mietzner
Journal:  J Med Chem       Date:  1994-11-25       Impact factor: 7.446

8.  CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site.

Authors:  John K Buolamwini; Haregewein Assefa
Journal:  J Med Chem       Date:  2002-02-14       Impact factor: 7.446

9.  CoMFA and CoMSIA studies on 1,3-bis(benzylidene)-3,4-dihydro-1H-naphthalen-2-one, 2,6-bis(benzylidene)cyclohexanone, and 3,5-bis(benzylidene)-4-piperidone series of cytotoxic compounds.

Authors:  Maulik R Patel; Jonathan R Dimmock; Tanaji T Talele
Journal:  J Chem Inf Model       Date:  2007-10-18       Impact factor: 4.956

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  3 in total

1.  3D-QSAR studies and molecular docking on [5-(4-amino-1H-benzoimidazol-2-yl)-furan-2-yl]-phosphonic acid derivatives as fructose-1,6-biphophatase inhibitors.

Authors:  Ping Lan; Mei-Qi Xie; Yue-Mei Yao; Wan-Na Chen; Wei-Min Chen
Journal:  J Comput Aided Mol Des       Date:  2010-10-20       Impact factor: 3.686

2.  A combined 3D-QSAR and molecular docking strategy to understand the binding mechanism of (V600E)B-RAF inhibitors.

Authors:  Zaheer Ul-Haq; Uzma Mahmood; Sauleha Reza
Journal:  Mol Divers       Date:  2012-10-04       Impact factor: 2.943

Review 3.  Quantum mechanics implementation in drug-design workflows: does it really help?

Authors:  Olayide A Arodola; Mahmoud Es Soliman
Journal:  Drug Des Devel Ther       Date:  2017-08-31       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.